Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

t is being prepared.

?These three Phase II clinical trials sponsored by NCI are components of a clinical trials program designed to identify signals of clinical activity of ispinesib across multiple tumor types,? stated Dr. Andrew A. Wolff, Cytokinetics Senior Vice President of Clinical Research and Development and Chief Medical Officer. ?Although these three trials did not meet the protocol-specified criteria for progression, we are encouraged by the anti-cancer activity of ispinesib observed to date in three other Phase II trials in breast, ovarian and non-small cell lung cancers. Based on these data, we plan to move forward in further clinical development of ispinesib with a focused approach to the potential treatment of breast cancer with ispinesib.?

Clinical Trials of Ispinesib

Ispinesib has been the subject of a broad Phase II clinical trials program under the sponsorship of GlaxoSmithKline (GSK) and is also being developed in collaboration with the NCI. GSK has sponsored three Phase II clinical trials, one evaluating ispinesib as second- or third-line treatment for patients with locally advanced or metastatic breast cancer, one evaluating ispinesib as second-line treatment for patients with non-small cell lung cancer, and one evaluating ispinesib as second-line treatment for patients with advanced ovarian cancer. Enrollment in all of these trials has been closed. To date, clinical activity with ispinesib has been observed in breast cancer, in non-small cell lung cancer, and ovarian cancer with the more robust clinical activity observed in a Phase II clinical trial evaluating ispinesib in the treatment of metastatic breast cancer patients that have failed treatment with taxanes and anthracyclines. In this clinical trial, The best overall responses observed with ispinesib were partial responses in 4 of 45 evaluable patients as measured by the RECIST criteria. Responses were confirmed by independent radiology review and were seen in
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
...  BioDelivery Sciences International, Inc. (Nasdaq: BDSI ... license and development agreement with Endo Pharmaceuticals (Nasdaq: ... to develop and commercialize BEMA Buprenorphine for the ... patented and proven BioErodible MucoAdhesive (BEMA) technology to ...
... conjunction with its fourth quarter 2011 earnings release (expected to ... Inc. (NYSE: CVD ) is pleased to invite ... will be broadcast live over the Internet on Thursday, January ... , What:       , , , Covance Fourth Quarter 2011 Earnings ...
Cached Medicine Technology:BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 2BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 3BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 4BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine 5
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... Jersey Institute of Technology (NJIT) today to join ... of the New Jersey Innovation Institute (NJII), an ... business innovation through the leveraging of industry, government, ... Cory Booker, Panasonic Corp. of North America Chairman ... Kim Guadagno, New Jersey Secretary of Higher Education ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making breakthroughs ... , A team of physician-scientists at UT Southwestern ... hormone with natural anti-depressant properties) works inside the brain. ... for depression in the form of a neuroprotective drug ... online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... (SACRAMENTO, Calif.) The risk of pregnancy among women ... sterilization is more than 10 times greater over a ... sterilization, a study by researchers at Yale University and ... in the medical journal Contraception , the study ... sterilization method marketed under the brand name Essure. ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... pain today are much less likely to die, or to experience ... according to a new international study. ,It's the first ... rate of heart failure and death over such a short time ... change occurred at the same time that hospitals increased their use ...
... failed to improve symptoms of moderate to severe chronic ... multi-center trial. ,The results of the ... the first issue of the May American Journal of ... Thoracic Society. ,According to an editorial commenting ...
... Junior doctors who do not get training posts through ... further misery because the government is stalling on ... warns. ,Latest figures show that 34,250 doctors ... The government has so far given no commitment that ...
... cream for enhancing sexual desire in female cancer survivors did ... Mayo clinic has shown. ,A low sex ... to a previous study which pointed a link between androgen ... levels, this new study was conducted on 150 post menopausal ...
... is now infusing roasted sunflower seeds with caffeine ... provide players and other people the extra energy needed to ... been under development since an year, are grown in North ... Products) plant at Willow Lake where caffeine, taurine, lysine and ...
... there is no hard and fast rule as to how a ... more than glad to endorse that view as standard positions ... motherly feelings to override. , Take the case of ... when her daughter Deborah was born. ,As manager of ...
Cached Medicine News:Health News:Good News for Sufferers of Heart Attack, Chest Pain 2Health News:Good News for Sufferers of Heart Attack, Chest Pain 3Health News:Good News for Sufferers of Heart Attack, Chest Pain 4Health News:Anti-inflammatory Drug Fails to Improve COPD Symptoms 2Health News:Junior Doctors Facing More Misery Because of Contract Deadlock: BMA 2Health News:Caffeinated Sunflower Seeds To Hit The Market 2Health News:New Research Promises To Take The Pain Off Breast Feeding 2Health News:New Research Promises To Take The Pain Off Breast Feeding 3
... solid made, manual plate washer for ... dispense and aspirate function ensure proper ... a stand and all necessary tubings. ... as well as any bottles for ...
... MP-1200 is a compact and simple ... internal micropumps enable the system both ... all types of microtiter well. MW-1200 ... in rows of 8 wells or ...
High precision microplate washer for immuno and adherent cell assays. For use with all strip types and full microplate in 96- and 384-well format in both portrait and landscape orientations....
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use....
Medicine Products: